The Mexico active pharmaceutical ingredients market was valued at USD 2.82 Billion in 2025 and is expected to grow at a CAGR of 4.50%, reaching USD 4.38 Billion by 2035. The market growth is driven by increased demand for generic drugs, supportive government initiatives, and expanding local manufacturing capabilities. Growing collaborations with international pharmaceutical firms and increasing investments in research and development are expected to drive market growth during the forecast period. Advances in biotechnology and personalized medicine are also expected to support future growth.
Base Year
Historical Period
Forecast Period
According to Patricia Alupo et al., 2025, the prevalence of chronic diseases in Mexico is around 2.5%, significantly driving the demand for active pharmaceutical ingredients and positively influencing the market’s overall growth trajectory.
Growing generic drug manufacturing, favorable regulatory support, and nearshoring trends are driving API production in Mexico, significantly contributing to the market’s expansion and reducing dependency on international supply chains.
Leading manufacturers are enhancing market growth through vertical integration, domestic capacity expansion, and adherence to international quality standards, ensuring stable supply and reinforcing Mexico’s position as a competitive API hub.
Compound Annual Growth Rate
4.5%
Value in USD Billion
2026-2035
*this image is indicative*
Active pharmaceutical ingredients (APIs) are vital components in drug manufacturing, responsible for producing the intended therapeutic effects in medications. Their quality, efficacy, and regulatory compliance significantly influence the overall performance of pharmaceutical products. The market was valued at USD 2.82 Billion in 2025. The market is witnessing steady growth due to rising healthcare demand, increased chronic disease prevalence, and expanding pharmaceutical manufacturing capabilities. Favorable government initiatives, foreign investments, and advancements in production technologies further support market development.
Rising Cancer Burden to Accelerate the Market Demand
The growing burden of cancer in Mexico is a key driver fueling the expansion of the active pharmaceutical ingredients (API) market. According to the Organisation for Economic Co-operation and Development (OECD), cancer remains the fourth leading cause of death in the country, with 1 in 14 premature deaths attributed to the disease. The report projects an average of 46,200 premature cancer-related deaths annually through 2050, reducing life expectancy by nearly one year. This rising demand for oncology treatments is expected to significantly drive growth in Mexico’s API market.
Some of the trends in the market include a strategic shift toward domestic API manufacturing and an increase in global collaborations.
Strategic Shift Toward Domestic API Manufacturing Poised to Enhance Market Growth in Mexico
A significant trend shaping the market is the government’s strategic focus on strengthening domestic pharmaceutical production to reduce dependency on imports. In July 2025, the administration introduced a national plan to boost local manufacturing capabilities, supported by targeted investments and regulatory reforms. This initiative includes incentives for API production, prioritization in public procurement, and the establishment of pharmaceutical infrastructure. Such policy shift is expected to enhance supply chain resilience and drive sustained growth in Mexico’s API market over the coming years.
Rising Global Collaborations Advancing Sustainable API Development in Mexico
The rise of global collaborations aimed at promoting sustainable API production is a significant trend shaping the market. In May 2023, Ginkgo Bioworks and Centrient Pharmaceuticals expanded their partnership to enhance eco-friendly enzymatic and fermentation-based manufacturing of essential antibiotics. With Centrient maintaining production facilities and sales offices in Mexico and globally, such alliances demonstrate the growing emphasis on green innovation. These rising collaborations are expected to strengthen Mexico’s API capabilities and support long-term market advancement through technology transfer and sustainable practices.
Cardiovascular Diseases to Witness Substantial Growth for the Market Share by Therapeutic Application
The market encompasses a wide range of therapeutic applications, including communicable diseases, oncology, cardiovascular diseases, respiratory diseases, pain management, diabetes, and others. Among these, the cardiovascular diseases segment is expected to lead the market. This dominance is primarily driven by the high prevalence and mortality rates associated with heart conditions. According to the National Institute of Statistics and Geography, heart diseases were the leading cause of death in Mexico in 2023, with over 97,000 reported cases. This alarming statistic underscores the growing demand for cardiovascular treatments, thereby boosting the consumption of APIs targeting heart-related ailments.
The key features of the market report comprise funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Novartis is an established pharmaceutical entity in Mexico, with operations focused on pharmaceutical manufacturing and clinical development. Its Mexican branches, such as Novartis de México, S.A. de C.V., contribute to local drug supply chains and broader healthcare initiatives. Though primarily engaged in finished pharmaceuticals, Novartis supplies key APIs through its global network and local distribution infrastructure. The company also advances health equity strategies that may influence API uptake and access across underserved Mexican communities.
Bayer supplies APIs indirectly in Mexico as part of its global pharmaceutical supply chain, supporting key therapeutic areas such as cardiovascular, oncology, and women’s health. While specific API production within Mexico isn't well-documented, the company ensures API availability through imports and its established logistics presence. Additionally, Bayer’s sustainability initiatives—such as securing renewable energy for Mexican facilities—reflect a broader commitment to responsible operations in the region.
Glenmark has a strong API presence in Mexico through its Latin American operations. Its API division in São Paulo covers key regulated markets, including Mexico, ensuring compliance with COFEPRIS. Glenmark maintains leadership in supplying APIs such as Bupropion, Cilostazol, and Olmesartan to Mexican pharmaceutical players, supported by its R&D and regulatory expertise.
GSK operates in Mexico with a local corporate presence focused on vaccines and therapeutic medicines. While specifics on local API production are limited, GSK’s global status as an API provider supports its Mexican supply chain. The company supports therapeutic categories like infectious diseases, HIV, respiratory and oncology, indicating that APIs for these therapies are imported or supplied via global sourcing and local distribution networks.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Merck KGaA, AstraZeneca Plc, Sanofi SA, Grupo Neolpharma, Chinoin, and Teva Pharmaceutical Industries Ltd.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Molecule
Market Breakup by Type
Market Breakup by Type of Drugs
Market Breakup by Therapeutic Application
Market Breakup by End User
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Molecule |
|
| Breakup by Type |
|
| Breakup by Type of Drugs |
|
| Breakup by Therapeutic Application |
|
| Breakup by End User |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share